5-甲氧基-1H-吡咯并[2,3-c]吡啶-2-羧酸 | 17288-36-7

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 5-甲氧基-1H-吡咯并[2,3-c]吡啶-2-羧酸
• 中文别名: 5-甲氧基-1氢-吡咯[2,3-C]吡啶-2-甲酸；5-甲氧基-1H-吡咯并[2,3-c]吡啶-2-甲酸
• 英文名称: 5-methoxy-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid
• CAS: 17288-36-7
• 化学式: C₉H₈N₂O₃
• mdl: MFCD08448208
• 分子量: 192.174
• InChiKey: FDTMPCXUIHRSEB-UHFFFAOYSA-N

物化性质

• 沸点：
  458.4±40.0 °C(Predicted)
• 密度：
  1.459

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  75.2
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险类别码：
  R20/21/22
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Methoxy-1h-pyrrolo[2,3-c]pyridine-2-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Methoxy-1h-pyrrolo[2,3-c]pyridine-2-carboxylic acid
CAS number: 17288-36-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H8N2O3
Molecular weight: 192.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-甲氧基-1H-吡咯并[2,3-c]吡啶-2-羧酸 在 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 potassium hydroxide 作用下， 以 二氯甲烷 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 92.58h， 生成 (R)-(3-aminopiperidin-1-yl)(2-(1-ethyl-5-methoxy-1H-pyrrolo[2,3-c]pyridin-2-yl)-1-methyl-1H-benzo[d]imidazol-5-yl)methanone
  参考文献：
  名称：

  [EN] 2 - (AZAINDOL- 2 -YL) BENZ IMIDAZOLES AS PAD4 INHIBITORS
  [FR] 2-(AZAINDOL-2-YL)BENZIMIDAZOLES UTILISÉS COMME INHIBITEURS DE PAD4

  摘要：

  式（I）的化合物，其中; R1为氢或C1-6烷基; R2为氢，C1-6烷基，全氟甲基C0-5烷基-O-，或C1-6烷氧基; R3为氢，C1-6烷基，或C1-6烷氧基C1-6烷基; R4为氢，C1-6烷基，全氟甲基C1-6烷基; 或未取代的C3-6环烷基C1-6烷基; A为C-R5或N; B为C-R6或N; D为C-R7或N; 但A、B和D中至少有一个为N; R5为氢或C1-6烷基; R6为氢或C1-6烷基; R7为氢，C1-6烷基，C1-6烷氧基，或羟基; R8为氢或C1-6烷基，但R4和R8中至少有一个为氢; R9为氢或羟基; R10为氢或C1-6烷基; 其盐是PAD4抑制剂，可能对多种疾病的治疗有用，例如类风湿关节炎、血管炎、系统性红斑狼疮、溃疡性结肠炎、癌症、囊性纤维化、哮喘、皮肤性红斑狼疮和银屑病。

  公开号：

  WO2014015905A1
• 作为产物：
  描述：

  5-甲氧基-1H-吡咯并[2,3-c]吡啶-2-羧酸乙酯 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 以80%的产率得到5-甲氧基-1H-吡咯并[2,3-c]吡啶-2-羧酸
  参考文献：
  名称：

  新环系双吡啶并[4',3':4,5]吡咯并[1,2-a:1',2'-d]吡嗪及其脱氮类似物的合成。

  摘要：

  新环系双吡啶并[4',3':4,5]吡咯并[1,2-a:1',2'-d]吡嗪-6,13-​​二酮及其脱氮类似物吡啶并[4''的衍生物,3'':4',5']pyrrolo-[1',2':4,5]pyrazino [1,2-a]indole-6,13-​​dione 通过四步序列方便地合成。前一个环系的对称衍生物是通过自缩合获得的。另一方面，6-氮杂吲哚羧酸与吲哚2-羧酸缩合得到脱氮类似物环系统。标题环系统的衍生物由国家癌症研究所（美国马里兰州贝塞斯达）测试，其中四种对 MCF7（乳腺癌细胞系）和/或 UO-31（肾癌细胞系）表现出适度的活性。

  DOI：

  10.3390/molecules190913342

文献信息

• [EN] 2,3-SUBSTITUTED AZAINDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS<br/>[FR] DÉRIVÉS D'AZAINDOLES SUBSTITUÉS EN 2 ET 3 DESTINÉS AU TRAITEMENT D'INFECTIONS VIRALES
  申请人：SCHERING CORP

  公开号：WO2009032125A1

  公开（公告）日：2009-03-12

  The present invention relates to 2,3-Substituted Azaindole Derivatives, compositions comprising at least one 2,3-Substituted Azaindole Derivatives, and methods of using the 2,3-Substituted Azaindole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

  本发明涉及2,3-取代吡唑吲哚衍生物，包括至少一种2,3-取代吡唑吲哚衍生物的组合物，以及使用这些2,3-取代吡唑吲哚衍生物治疗或预防患者病毒感染或与病毒相关的疾病的方法。
• [EN] 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS<br/>[FR] COMPOSÉS DE 8-MÉTHYL-1-PHÉNYL-IMIDAZOL[1,5-A]PYRAZINE
  申请人：ORGANON NV

  公开号：WO2011095556A1

  公开（公告）日：2011-08-11

  The present invention provides 8-methyl-1 -phenyl-imidazo[1,5-a]pyrazine derivatives according to formula I or pharmaceutically acceptable salts thereof. The compounds of the current invention show inhibitory activity against Lck and can be used for the treatment of Lck-mediated diseases or Lck-mediated conditions such as inflammatory disorders.

  本发明提供了根据式I或其药学上可接受的盐制备的8-甲基-1-苯基-咪唑并[1,5-a]吡嗪衍生物。本发明的化合物显示对Lck的抑制活性，可用于治疗由Lck介导的疾病或Lck介导的炎症性疾病。
• [EN] AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS<br/>[FR] COMPOSÉS AMINOCARBAMOYLE DESTINÉS AU TRAITEMENT D'INFECTIONS VIRALES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2022043374A1

  公开（公告）日：2022-03-03

  The present invention relates to compounds of formula (II) wherein R1-R5, X and L are as described herein, and pharmaceutically acceptable salts thereof, compositions including the compounds and methods of using the compounds, particularly in the treatment and prophylaxis of coronavirus infection.

  本发明涉及公式（II）中的化合物，其中R1-R5，X和L如本文所述，并其药用盐，包括该化合物的组合物和使用该化合物的方法，特别是用于治疗和预防冠状病毒感染。
• [EN] 2 - (AZAINDOL- 2 -YL) BENZ IMIDAZOLES AS PAD4 INHIBITORS<br/>[FR] 2-(AZAINDOL-2-YL)BENZIMIDAZOLES UTILISÉS COMME INHIBITEURS DE PAD4
  申请人：GLAXO GROUP LTD

  公开号：WO2014015905A1

  公开（公告）日：2014-01-30

  Compounds of formula (I) wherein; R1 is hydrogen or C1-6alkyl; R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O-, or C1-6alkoxy; R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl; R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl; or unsubstituted C3-6cycloalkylC1-6alkyl; A is C-R5 or N; B is C-R6 or N; D is C-R7 or N; with the proviso that at least one of A, B, and D, is N; R5 is hydrogen or C1-6alkyl; R6 is hydrogen or C1-6alkyl; R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy; R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen; R9 is hydrogen or hydroxy; R10 is hydrogen or C1-6alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.

  式（I）的化合物，其中; R1为氢或C1-6烷基; R2为氢，C1-6烷基，全氟甲基C0-5烷基-O-，或C1-6烷氧基; R3为氢，C1-6烷基，或C1-6烷氧基C1-6烷基; R4为氢，C1-6烷基，全氟甲基C1-6烷基; 或未取代的C3-6环烷基C1-6烷基; A为C-R5或N; B为C-R6或N; D为C-R7或N; 但A、B和D中至少有一个为N; R5为氢或C1-6烷基; R6为氢或C1-6烷基; R7为氢，C1-6烷基，C1-6烷氧基，或羟基; R8为氢或C1-6烷基，但R4和R8中至少有一个为氢; R9为氢或羟基; R10为氢或C1-6烷基; 其盐是PAD4抑制剂，可能对多种疾病的治疗有用，例如类风湿关节炎、血管炎、系统性红斑狼疮、溃疡性结肠炎、癌症、囊性纤维化、哮喘、皮肤性红斑狼疮和银屑病。
• 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS
  申请人：de Man Adrianus Petrus Antonius

  公开号：US20120309966A1

  公开（公告）日：2012-12-06

  The present invention provides 8-methyl-1-phenyl-imidazo[1,5-a]pyrazine deriva-tives according to formula I or pharmaceutically acceptable salts thereof. The compounds of the current invention show inhibitory activity against Lck and can be used for the treatment of Lck-mediated diseases or Lck-mediated conditions such as inflammatory disorders.

  本发明提供了按式I或其药学上可接受的盐所表示的8-甲基-1-苯基咪唑[1,5-a]吡嗪衍生物。本发明的化合物显示出对Lck的抑制活性，并可用于治疗由Lck介导的疾病或Lck介导的炎症性疾病状态。